Cookies on this site

Congratulations to Adam Mead, who has been appointed Director of Oxford Cancer. Professor Mead joins Professors Mark Middleton and Tim Elliott in leading Oxford’s interdisciplinary cancer research community.

Professor Adam Mead is Professor of Haematology at the University of Oxford, Consultant Haematologist at Oxford University Hospitals NHS Foundation Trust, and Deputy Director of the MRC Weatherall Institute of Molecular Medicine based at the Radcliffe Department of Medicine. His research focuses on understanding the genetic and cellular complexity of myeloproliferative neoplasms and related blood cancers, with the aim of developing more precise and effective treatments for patients.   

Speaking about his appointment, Professor Mead said:

I am delighted to join Mark and Tim in leading Oxford Cancer at such an exciting time for cancer research in Oxford. The strength of collaboration across the University, our NHS partners, and industry creates enormous opportunities to accelerate progress for patients. I look forward to working with colleagues across disciplines to support innovation and strengthen our cancer research community.

Recent stories

European grant to investigate how tissue ageing influences cancer development

An international team of researchers, including Professor Alison Simmons, has been awarded a €13.97 million Synergy Grant from the European Research Council (ERC) to investigate how ageing in tissues influences the development of cancer.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.